by Matthew Johnson | Mar 5, 2019 | Standing, Time Limits
By Alex Li and Matt Johnson On January 31, 2019, the Patent Trial and Appeal Board issued a decision granting institution of inter partes review in Sling TV, L.L.C. v. Realtime Adaptive Streaming, L.L.C., No. IPR2018-01331, where the Board held that a patent...
by Matthew Johnson | Feb 18, 2019 | Trial Institution
By Lisa Furby, David Anderson, Mike Lavine, and Matt Johnson Last week the Chicago-Kent Journal of Intellectual Property published a comment prepared by a team of Jones Day attorneys that analyzed whether the PTAB is treating multiple petitions filed against a common...
by Matthew Johnson | Feb 11, 2019 | Amendment Practice, Claim Construction, PTAB Trial Basics
Patent Trial and Appeal Board, or PTAB, defense litigation strategies continue to evolve. In a recent Law360 article, Jones Day Intellectual Property lawyers Dave Cochran, Mike Hendershot, and Matt Johnson explained why previous assumptions and strategies pertaining...
by Matthew Johnson | Jan 31, 2019 | Federal Circuit Appeal, Pharmaceutical, Standing
By Mike Lavine and Matt Johnson Mylan Pharmaceuticals, Inc. petitioned for inter partes review (IPR) of U.S. Patent No. 6,858,650 (the “‘650 Patent”), which is owned by UCB Pharma GmbH (“UCB”) and is directed to chemical derivatives of a drug for treating urinary...
by Matthew Johnson | Jan 28, 2019 | PGR
By Sue Gerber and Matt Johnson The America Invents Act (“AIA”), also called the Patent Reform Act of 2011, was enacted to overhaul the U.S. patent system and harmonize the domestic patent laws with those in the rest of the world. The AIA also created new procedures...
